Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Da	ita Sheet 37 CER 1 76	Attorney Docket Number	05986/100M724-US1			
<b>Application Data Sheet 37 CFR 1.76</b>		Application Number				
Title of Invention	B. ANTHRACIS PREVENTION AND TREATMENT; MUTANT B. ANTHRACIS LACKING LUXS ACTIVITY AND FURANONE INHIBITION OF GROWTH, AI-2 QUORUM SENSING, AND TOXIN PRODUCTION					
The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the						

bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.

This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.

Secre	су	Order 37	CFR 5.2									
											Secrecy Order pur electronically.)	suant to
Appli	caı	nt Informa	ation:									
Applic	ant	1									Remove	
Applic	ant	Authority •	Inventor OL	_egal	Representativ	e unde	er 35 l	J.S.C. 11	7	OParty of In	terest under 35 U.S.	.C. 118
Prefix	Prefix Given Name				Middle Na	me			Fan	nily Name		Suffix
	Ma	ircus			В.				Jone	es		
Resid	lenc	e Informatio	n (Select One)	$\overline{}$	) US Residenc	<del>-                                    </del>	O No	n US Re		<del></del>	e US Military Service	;
City	Ro	ckville		St	ate/Province	e M	1D	Countr	y of I	Residence i	US	
Citizei	nshi	p under 37 C	FR 1.41(b) i	US	3							
Mailin	g A	ddress of Ap	plicant:									
Addre	ss 1		9712 Medical	Cent	er Dr.							
Addre	ss 2											
City		Rockville					Stat	e/Provir	nce MD			
Postal	l Co	de	20850			Cou	ntry	US				
Applic	ant	2									Remove	
Applic	ant	Authority 🗨	Inventor OL	_egal	Representativ	e unde	er 35 l	J.S.C. 11	7	OParty of In	terest under 35 U.S.	.C. 118
Prefix	Gi	ven Name			Middle Na	me			Fan	nily Name		Suffix
		ırtin			J. Blaser							
	lenc	e Informatio	n (Select One)	$\overline{}$	US Residency Non US Residency Active US Military Service					<del>)</del>		
City				C	ountry Of Re	siden	ıcei					
		p under 37 C		US	3							
Mailin	g A	ddress of Ap	plicant:									
Addre	ss 1		9 Washington	Mew	'S							
Addre	ss 2											
City		New York	<u></u>				Stat	e/Provir	ice	NY		
Posta	Postal Code 10003 Countryi US											
Applic	Applicant 3											
Applic	Applicant Authority Inventor							.C. 118				
Prefix		ven Name			Middle Na	me			Fan	nily Name		Suffix
	Th	omas							Woo	od		
Resid	enc	e Informatio	n (Select One)	•	US Residenc	у	) No	n US Re	sidenc	y Active	e US Military Service	)
City	To	lland		St	ate/Province	• C	т [	Countr	y of I	Residence i	US	

		Under the F	aperwo	ork Reduction Act	of 1995, no	persons are	required	to respond		nt and Trac	lemark Office; <sup>l</sup>	through 06/30/2010. OMI U.S. DEPARTMENT OF 0 contains a valid OMB cor	COMMERCE
					ED 4 =	Attor	ney D	ocket N	umber	05986/100M724-US1			
Appli	ıcat	ion Da	ta S	heet 37 C	FR 1.7	6 Appl	Application Number						
Title of Invention B. ANTHRACIS PREVENT AND FURANONE INHIBIT													
Citize	Citizenship under 37 CFR 1.41(b) i US												
Mailin	g A	ddress	of Ap	plicant:	,								
Addre	ess 1			15 Doe Rur	1								
Addre	ess 2	2											
City		Tolland						Stat	te/Provir	псе	СТ		
Posta	l Co	de		06084			Co	ountryi	US		Į.		
Annlie	cant	1										Remove	
	Applicant 4  Applicant Authority Inventor Clegal Representative under 35 U.S.C. 117  Party of Interest under 35 U.S.C. 118						.C. 118						
Prefix Given Name				Middle Name			Family Name Su			Suffix			
	Da	cheng							Ren				
Resid	denc	e Inforn	natio	n (Select O	ne) 💿 l	IS Residency			e US Military Service	 Э			
City	lth	aca		<del>-</del>	Sta	te/Provin	Province NY Country of F			y of Re	sidence i	US	
Citize	nshi	p under	37 C	FR 1.41(b)	i CN		-	1					
Mailin	g A	ddress o	of Ap	plicant:	I								
Addre	ess 1			201 Maple	Avenue, A	Apt. B #23							
Addre	ess 2	2											
City		Ithaca					State/Province			nce	NY		
Posta	l Co	de		14850			Co	ountry	US				
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the <b>Add</b> button.													
Corre	Correspondence Information:												
				Number or 1 see 37 CF			orresp	ondend	ce Inforn	nation s	section be	elow.	
<b>□ Δ</b>	An Address is being provided for the correspondence Information of this application												

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).						
An Address is being provided for the correspondence Information of this application.						
Customer Number 07278						
Email Address	pludwig@darbylaw.com	Add Email	Remove Email			

## **Application Information:**

Title of the Invention	B. ANTHRACIS PREVENTION AND TREATMENT; MUTANT B. ANTHRACIS LACKING LUXS ACTIVITY AND FURANONE INHIBITION OF GROWTH, AI-2 QUORUM SENSING, AND TOXIN PRODUCTION				
Attorney Docket Number	05986/100M724-U	S1	Small Entity Status Claimed ⊠		
Application Type	Nonprovisional				
Subject Matter	Utility				
Suggested Class (if any)			Sub Class (if any)		
Suggested Technology C	enter (if any)	1645			
Total Number of Drawing	Sheets (if any)	22	Suggested Figure for Publication (if any)		

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

			10 100po.ia to a conconc			a valid offic officialist.	
Application Data Sh	aat 37 CED 1 76	Attorney D	ocket Number	05986/100M	/1724-US1		
Application Data Sil	eet 37 CT K 1.70	Application	n Number				
	THRACIS PREVENTION FURANONE INHIBITION						
Publication Information:							
Request Early Public	ation (Fee required at	time of Red	uest 37 CFR 1.2	19)			
Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.  C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.							
Representative Information:							
Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Enter either Customer Number or complete the Representative Name section below. If both sections are completed the Customer Number will be used for the Representative Information during processing.							
Please Select One:	Customer Number	Us	Patent Practitioner	r 🔵 Lir	mited Recogn	ition (37 CFR 11.9)	
Customer Number	07278			<b>'</b>			
Domestic Benefit/National Stage Information:  This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be made part of the specification.							
Prior Application Status	EXPIRED				Rei	move	
Application Number	Continuity <sup>-</sup>	Гуре	Prior Application Number Fil		Filing Da	Filing Date (YYYY-MM-DD)	
	non provisional of		60462254		2003-04-11		
Prior Application Status	Expired				Rei	move	
Application Number	Continuity <sup>-</sup>	Гуре	Prior Application Number Filir		Filing Da	Filing Date (YYYY-MM-DD)	
	non provisional of		60462255		2003-04-11		
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the Add button.							
Foreign Priority Information:							
This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).							
Application Number	Country	, i	Parent Filing Da	ate (YYYY-N		Priority Claimed	
7 (PPIIOGGOTI TIGITIDEI	Country	,	, arching De	ис (1111 <u>-</u> 1		○ Yes ○ No	
Additional Foreign Priority Data may be generated within this form by selecting the  Add button.							

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Da	ata Shaat 37 CED 1 76	Attorney Docket Number	05986/100M724-US1	
Application Data Sheet 37 CFR 1.76		Application Number		
Title of Invention	B. ANTHRACIS PREVENTION AND TREATMENT; MUTANT B. ANTHRACIS LACKING LUXS ACTIVITY AND FURANONE INHIBITION OF GROWTH, AI-2 QUORUM SENSING, AND TOXIN PRODUCTION			

## **Assignee Information:**

<u> </u>							
Providing this information in the application data sheet does not substitute for compliance with any requirement of part 3 of Title 37 of the CFR to have an assignment recorded in the Office.							
Assignee 1	Assignee 1						
If the Assignee is an Organization check here.							
Organization Name	Iniversity of Connecticut						
Mailing Address Information:							
Address 1	263 Farmington Avenue						
Address 2							
City	Farmington	State/Province	СТ				
Country <sup>i</sup>		Postal Code	06030-6207				
Phone Number		Fax Number					
Email Address		•					
Assignee 2							
If the Assignee is an Orga	nization check here.						
Organization Name N	lew York University						
Mailing Address Informa	ation:						
Address 1	70 Washington Square South						
Address 2							
City	New York	State/Province	NY				
Country <sup>i</sup>		Postal Code	10012				
Phone Number		Fax Number					
Email Address		•					
Additional Assignee Data may be generated within this form by selecting the Add button.							

## Signature:

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.						
Signature	/FB/ Flynn Barrison (5	3,970)	Date (YYYY-MM-DD)	2008-03-11		
First Name	S.	Last Name	Ludwig	Registration Number	25351	

PTO/SB/14 (07-07) Approved for use through 06/30/2010. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Da	nta Sheet 37 CFR 1.76	Attorney Docket Number	05986/100M724-US1	
Application Da	ita Sileet 37 Cl K 1.70	Application Number		
Title of Invention	B. ANTHRACIS PREVENTION AND TREATMENT; MUTANT B. ANTHRACIS LACKING LUXS ACTIVITY AND FURANONE INHIBITION OF GROWTH, AI-2 QUORUM SENSING, AND TOXIN PRODUCTION			

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** 

## **Privacy Act Statement**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.